IMO: IXC SP hinges on FDA opinion. Harmonisation should see us to 1.30 around CR price. However, if the opinion goes against IXC - we may see new lows even if this is somewhat priced in.
Further CR or just progressing with EMA will see SP suffer.
The clear strengths of the asset, orphan and patent protection, unencumbered market ect unfortunately means nothing to SP at this point. We will see a base from 70-90 until FDA decision.
70:30 risk in favour of trial harmonisation IMO. Not without risk though asymmetric which is why I am (and most of us) are still here.
If harmonisation is achieved then the other clear benefits of IXC and presendin will come into play and help SP higher.
Until then, accumulate, patience, and nerves are the name of this long base until Q3 decision.
Can anyone offer insight to chances of harmonisation? Other then 51 Cap's Scott who rates it as a good chance I note (he has incentives)
IXC Price at posting:
77.5¢ Sentiment: Buy Disclosure: Held
